6534 — CH Biotech R&D Co Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsAdventurousSmall CapNeutral

Annual income statement for CH Biotech R&D Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	841	702	1,019	1,434	1,515
Cost of Revenue
Gross Profit	697	590	848	1,135	1,260
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	583	557	659	923	949
Operating Profit	258	145	359	511	566
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	242	127	360	566	579
Provision for Income Taxes
Net Income After Taxes	190	100	291	465	463
Net Income Before Extraordinary Items
Net Income	190	100	291	465	463
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	190	100	291	465	463
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.98	1.02	2.97	4.72	4.73
Dividends per Share